Latest filings (excl ownership)
6-K
Current report (foreign)
22 Apr 24
6-K
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
16 Apr 24
6-K
Current report (foreign)
15 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
3 Apr 24
6-K
Current report (foreign)
2 Apr 24
6-K
Current report (foreign)
25 Mar 24
6-K
Current report (foreign)
21 Mar 24
6-K
Completion of share buy-back program
18 Mar 24
6-K
Genmab Announces Initiation of Share Buy-Back Program
15 Mar 24
6-K
Current report (foreign)
13 Mar 24
6-K
Passing of Genmab A/S’ Annual General Meeting
13 Mar 24
6-K
Current report (foreign)
11 Mar 24
6-K
Current report (foreign)
4 Mar 24
6-K
Current report (foreign)
4 Mar 24
6-K
Current report (foreign)
1 Mar 24
6-K
Current report (foreign)
29 Feb 24
6-K
Current report (foreign)
28 Feb 24
6-K
Capital Increase in Genmab as a Result of Employee Warrant Exercise
27 Feb 24
6-K
Current report (foreign)
26 Feb 24
6-K
Current report (foreign)
26 Feb 24
6-K
Current report (foreign)
23 Feb 24
6-K
Current report (foreign)
23 Feb 24
S-8
Registration of securities for employees
22 Feb 24
6-K
Current report (foreign)
20 Feb 24
6-K
Notice to Convene the Annual General Meeting of Genmab A/S
15 Feb 24
6-K
Genmab Announces Initiation of Share Buy-Back Program
14 Feb 24
20-F
2023 FY
Annual report (foreign)
14 Feb 24
6-K
Genmab 2023 Annual Report
14 Feb 24
6-K
Current report (foreign)
31 Jan 24
6-K
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023
23 Jan 24
6-K
Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
22 Jan 24
6-K
Current report (foreign)
3 Jan 24
6-K
Current report (foreign)
13 Dec 23
6-K
Capital Increase in Genmab as a Result of Employee Warrant Exercise
5 Dec 23
6-K
Current report (foreign)
1 Dec 23
6-K
Current report (foreign)
21 Nov 23
6-K
Major Shareholder Announcement
9 Nov 23
6-K
Major Shareholder Announcement
8 Nov 23
6-K
Genmab Announces Financial Results for the First Nine Months of 2023
7 Nov 23
Latest ownership filings
144
Notice of proposed sale of securities
1 Mar 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
BlackRock Inc.
2 Feb 24
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
6 Feb 23
SC 13G/A
BlackRock Inc.
1 Feb 23
SC 13G/A
BlackRock Inc.
3 Feb 22
SC 13G/A
BlackRock Inc.
29 Jan 21
SC 13G
Beneficial ownership report
7 Feb 20